Welcome to our dedicated page for Marvel Biosciences news (Ticker: MBCOF), a resource for investors and traders seeking the latest updates and insights on Marvel Biosciences stock.
Marvel Biosciences Corp. (OTCQB: MBCOF) generates news primarily around its pre-clinical drug development programs in neurological and neurodevelopmental disorders. Through its subsidiary Marvel Biotechnology Inc., the company focuses on MB-204, a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline, which targets the adenosine A2A receptor.
News updates for Marvel often highlight preclinical study results and scientific recognition. The company has reported data showing strong preclinical efficacy of MB-204 in models of autism, Rett syndrome and depression, as well as reductions in tau hyperphosphorylation in an acute Alzheimer's disease study. Marvel also announces invitations to present at major scientific meetings, such as the Alzheimer's Association International Conference and the International Rett Syndrome Foundation Scientific Meeting, where it shares findings on MB-204 in Alzheimer's disease, Rett syndrome and autism spectrum disorder.
Investors and followers can also expect regular coverage of Marvel's capital markets activities. The company issues news releases about non-brokered private placements of units, the terms of common share purchase warrants, and any acceleration of warrant expiry dates triggered by trading price thresholds on the TSX Venture Exchange. Additional corporate news includes grants of deferred share units to directors in lieu of cash fees, with details on vesting and settlement conditions.
This news page provides a centralized view of Marvel Biosciences' scientific progress, financing transactions and corporate developments related to MB-204. Readers interested in the evolution of the company’s pre-clinical pipeline and its engagement with the neurology and neurodevelopmental research community can use this feed to follow key milestones and disclosures over time.
Marvel Biosciences has announced significant results from its preclinical Rett syndrome study comparing MB-204 to Trofinetide. The study revealed that MB-204, administered at 10 mg/kg orally once daily, demonstrated superior and longer-lasting effects compared to Trofinetide (100 mg/kg injected).
Key findings show MB-204 maintained effectiveness for up to three weeks after treatment cessation, significantly outperforming Trofinetide in reversing social behavioral deficiencies. The drug showed remarkable results in multiple behavioral tests, including nose contacts, paw contacts, and following episodes (p<0.0001 vs control).
The research, conducted at the iBraiN Institute, will be presented at the International Rett Syndrome Foundation Scientific Meeting in Boston, June 2025. Scientists noted MB-204's potential as a novel treatment for both Rett syndrome and autism, highlighting its sustained effectiveness without reduction after chronic dosing.
Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) has been selected to present at the International Rett Syndrome Foundation (IRSF) Scientific Meeting from June 9-11th, 2025. Dr. Mark Williams, Chief Science Officer, will present the company's latest preclinical studies of MB-204 in Rett Syndrome and Autism Spectrum Disorder (ASD).
The research was conducted in collaboration with Dr. Julie Le Merrer and Dr. Jérôme Becker from the iBraiN Institute in Tours, France, producing promising preclinical data. The company plans to publish full study results in a peer-reviewed journal and is preparing to submit an application for Orphan Drug Designation for MB-204 as a Rett syndrome treatment with the U.S. FDA.
Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF) has been selected to present groundbreaking Alzheimer's disease research at the prestigious Alzheimer's Association International Conference in July 2025.
The presentation will showcase preclinical data from their acute Alzheimer's study, conducted with Professor Emmanuel Planel, focusing on their compound MB-204. The research demonstrated significant reduction in tau hyperphosphorylation in mice, suggesting potential as a disease-modifying therapy.
Additionally, Marvel is conducting a chronic Alzheimer's study using the 5xFAD model, backed by an Alberta Innovates grant. This ongoing research evaluates MB-204's effects on cognition, behavior, and disease pathology, with results expected in Q3 2025.
Marvel Biosciences (TSXV: MRVL) has closed the first tranche of a non-brokered private placement, raising $1,000,000 through the issuance of 8,000,000 units at $0.125 per unit. The total offering aims to raise up to $1.5 million through 12,000,000 units.
Each unit consists of one common share and one purchase warrant exercisable at $0.175 per share for two years. The warrant expiry can be accelerated if the stock trades at $0.30 or higher for 10 consecutive trading days.
The company paid $54,950 in finder's fees and issued 383,600 finder's warrants. Proceeds will fund drug formulation, toxicology studies, and working capital. The securities are subject to a four-month hold period.
Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF) has announced plans to file for Orphan Drug Designation (ODD) with the FDA for MB-204 as a potential treatment for Rett Syndrome. The decision follows promising preclinical data showing MB-204's superior performance compared to Trofinetide, the only FDA-approved treatment for the disease.
The preclinical study, conducted with the iBraiN Institute and led by Drs. Julie le Merrer and Jerome Becker, evaluated MB-204's efficacy in a Rett Syndrome mouse model, focusing on social interaction, memory, and repetitive behaviors.
ODD is a regulatory pathway supporting treatments for rare diseases affecting fewer than 200,000 individuals in the U.S. The designation offers several benefits including:
- Market exclusivity
- Tax credits
- Waived FDA user fees
- Access to expedited programs like fast-track and priority review
Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) has released partial final data from its preclinical Rett syndrome study comparing its lead compound MB-204 with Trofinetide, the only FDA and Health Canada approved treatment for the condition.
The study, conducted with the iBraiN Institute, demonstrated that MB-204 (10 mg/kg oral daily) significantly outperformed Trofinetide (100 mg/kg injected daily) across multiple endpoints in Mecp2 mice over a two-week treatment period:
- MB-204 reversed social behavioral deficiencies in nose and paw touching (p<0.0001 vs control)
- MB-204 reversed impairments in following behaviour (p<0.0001 vs control)
- Both treatments improved social preference behaviour in the three-chamber test
- MB-204 reversed spontaneous alternations and same arm returns in Y-maze test (p<0.0001 vs control)
Analysis of the carry-over effects is ongoing and will be released separately. The company plans to publish and present the data at an upcoming scientific conference.
Marvel Biosciences Corp (TSXV: MRVL) (OTCQB: MBCOF) has announced its participation in the upcoming Bloom Burton & Co. Healthcare Investor Conference, scheduled for May 5-6, 2025, at the Metro Toronto Convention Centre.
The conference will facilitate connections between U.S., Canadian, and international investors interested in Canadian healthcare developments. CEO Rod Matheson and CSO Mark Williams will deliver a group presentation and engage in one-on-one meetings with potential investors during the event.
Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) has received a notice of allowance from the Chinese patent office for its lead compound MB-204, marking the first worldwide allowance for this patent family. MB-204 is a novel fluorinated derivative of Istradefylline, an approved Parkinson's drug, which Marvel is developing for neurological conditions including autism, depression, and Alzheimer's Disease.
The company has completed cGMP synthesis and 4-week GLP toxicology studies for MB-204 and is preparing for clinical trials. This patent allowance secures key composition of matter intellectual property protection in China, with the company anticipating similar notices from other countries.
Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF) has reported promising new data from its preclinical Rett syndrome study of MB204, conducted with the iBraiN Institute. The study compared MB204 to Trofinetide, the only FDA and Health Canada approved Rett syndrome treatment. Key findings show MB204 demonstrated sustained post-treatment benefits lasting 21 days, outperforming Trofinetide's 14-day effects. The company plans to pursue FDA Orphan and rare disease designation for MB204, which could provide market exclusivity and other benefits. Full study results are expected in Q1 2025.
Marvel Biosciences has been awarded a $300,000 Alberta Innovates AICE Validates grant to support the preclinical validation of MB204 for Alzheimer's disease treatment. The company's drug candidate, MB204, is an adenosine A2A receptor antagonist designed to target the underlying pathology of Alzheimer's, rather than just managing symptoms. The company has completed cGMP synthesis and 4-week GLP toxicology studies, and will conduct a chronic long-term preclinical study to validate MB204's effectiveness before moving to Phase 1 clinical trials.